USHealthcare

Pfizer Inc (PFE)

US · Healthcare · Drug Manufacturers - General

$25.41+1.52%
Last close · 2026-08-04

Latest quarter · ended 2026-03-31

Revenue
$14.45B
Revenue YoY
+5.4%
Net profit
$2.69B
Profit YoY
-9.4%
EPS
$0.75
EPS estimate
$0.72
Net margin
18.6%

EPS came in at 0.75 against a street estimate of 0.72 — a beat of 4.2%.

Key statistics

Market cap
$143.34B
P/E
19.1
Forward P/E
8.5
P/B
1.58
Book value
$15.81
EPS (TTM)
$1.31
Dividend yield
6.90%
52-week high
$27.80
52-week low
$22.03
50-day MA
$25.08
200-day MA
$25.83
Beta
0.31

Analyst view

Analysts rate Pfizer Inc a buy (9 buy, 15 hold, 1 sell out of 25) with an average price target of $28.75.

Shareholding

Insiders
0.10%
Institutions
69.55%

Largest institutional holders

FundStake
BlackRock Inc8.74%
Vanguard Capital Management, LLC6.48%
State Street Corp5.29%
Geode Capital Management, LLC2.34%
Vanguard Portfolio Management, LLC2.05%
Fisher Asset Management, LLC1.84%
Morgan Stanley - Brokerage Accounts1.63%
Northern Trust Corp1.09%

Recent filings & reports

DocumentDate
Reg FD disclosure · Q2 20262026-06-18
Board / officer change · Q2 20262026-06-18
Quarterly report · Q1 20262026-05-05
Results announced · Q2 20262026-05-05
Shareholder vote results · Q2 20262026-04-27
Proxy statement · Q2 20262026-03-12
Annual report FY20252026-02-26
Quarterly report · Q3 20252025-11-04

Readable in the app.

Corporate actions

ActionDetailDate
Dividend$0.43 / share
ex-date Jul 24, 2026 · pay Sep 1, 2026
2026-07-24
Dividend$0.43 / share
ex-date May 8, 2026 · pay Jun 12, 2026
2026-05-08
Dividend$0.43 / share
ex-date Jan 23, 2026 · pay Mar 6, 2026
2026-01-23
Dividend$0.43 / share
ex-date Nov 7, 2025 · pay Dec 1, 2025
2025-11-07
Dividend$0.43 / share
ex-date Jul 25, 2025 · pay Sep 2, 2025
2025-07-25

Deals & corporate news

AnnouncementDate
Full-year 2026 guidance provided; 2025 revenue guidance revised
On December 16, 2025, Pfizer issued an 8-K filing to disclose updated financial guidance. The company provided full-year 2026 guidance and revised its full-year 2025 revenue guidance downwar
2025-12-16
Completed acquisition of Metsera for approximately $7.0 billion
Pfizer completed its acquisition of Metsera, Inc. on November 13, 2025, for an upfront payment of $65.60 per share in cash, valuing the company at approximately $7.0 billion in enterprise va
2025-11-13

See the full picture

Technicals, trade setups with a published hit rate, $AI analysis and earnings-call summaries for Pfizer Inc — free to start.

Google PlayApp Store

Other Healthcare companies

Data updated 2026-08-05.